Objectives: Carbon Monoxide (CO), the third most common cause of acute poisoning death, is easily overlooked in the emergency department (ED). Nonspecific complaints such as headache, weakness, or malaise may easily result in misdiagnosis. The objectives of this study are to determine the frequency of CO poisoning in patients presenting to the ED complaining of headaches and to determine the feasibility of using noninvasive CO analyzers as a screening tool.
INTRODUCTION
Particularly in its milder forms, carbon monoxide (CO), the third most frequent cause of acute poisoning death, is easily unnoticed in the ED setting. Patients often present to the ED with nonspecific complaints of headache, weakness, or malaise and may be easily misdiagnosed with migraine or viral syndrome. When misdiagnosed, these patients may return to a hazardous environment and continue to be exposed to CO. Since CO is generated by the incomplete combustion of any organic substance, exposure is potentially very common: especially in a modern society that uses hydrocarbon powered vehicles and machinery. Exposure to CO is more likely during the colder months, but may occur at any time throughout the year and should be kept in the differential of ED patients with headaches [1] .
Traditionally, the diagnosis of CO poisoning required a draw of arterial or venous levels; in recent years however, readily available noninvasive CO breath analyzers have been a rapid and reliable method of determining carboxyhemoglobin (COHb) levels [2] . Although relatively inexpensive, breath analyzers have never been evaluated as a screening tool for adult ED patients with headaches.
The purpose of this clinical study was twofold:
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Noninvasive Measurement of Carbon Monoxide Levels in ED Patients with Headache of headaches with or without other associated symptoms. 2. To determine the feasibility of using noninvasive CO analyzers as a screening tool to determine which patients should receive formal CO testing.
MATERIALS AND METHODS
This was a prospective controlled clinical study utilizing a convenience sample of adult patients presenting to the EDs in two active community teaching hospitals in Northeast Pennsylvania; the study took place from In addition, we similarly recruited control subjects (who presented to the ED with complaints of minor trauma but no headache) and matched for age, gender, and smoking status over the same timeframe. Control subjects were used to determine the baseline CO levels in our patient population. Consent was obtained, and all subjects and controls were asked to fill out a brief questionnaire prior to the breath analysis. The questionnaire addressed smoking status (active/passive), time since last cigarette, age, type of vehicle and home heating source. Study subjects were asked to hold their breath for 20 seconds and then breathe into the Micro CO Breath Analyzer (Micro Medical Limited, Rochester, Kent, UK) [3] . The CO levels were displayed in units of ppm and %COHb. A microprocessor detects peak expired concentrations of alveolar gas. This is then converted to %COHb using the mathematical relationship described by Jarvis et al. for concentrations below 90 ppm [4] . Individuals with elevated breath COHb levels (nonsmokers >2%, smokers >5%), according to the usual standards for our hospital laboratory, underwent confirmatory blood serum level analysis. In patients with a normal breath CO level, no further CO testing was done. Therapeutic interventions in patients with elevated levels were left to the discretion of the treating physician. The Internal Review Boards of both hospitals approved the study. All comparisons were by Chi square with alpha set at 0.05.
RESULTS
We enrolled a total of 170 ED patients who met inclusion criteria of atraumatic, afebrile headaches and 98 controls matched for age, sex, and smoking status. Overall, 12 of 170 (7.1%) of our study group had elevated breath CO levels compared to only 1 of 98 (1.0%) of the control group (p = 0.025). Of the 12 positive study subjects, 8 were smokers and 4 were non-smokers; 9 had blood serum levels drawn, all of which confirmed the elevated levels provided by the noninvasive analyzer ( Table 1) . There were no statistically significant differences between the matched controls and study groups with regard to age, gender, smoking status, secondhand smoke exposure, or home heating source (P > 0.17) ( Table 2) .
DISCUSSION
Although breath analysis for CO measurement has been available for many years, its use has been largely limited to occupational, industrial, and public health settings; more recently it has been employed for smoking cessation programs. To our knowledge, this is only the third study to utilize breath analysis of CO as a diagnostic device in the ED setting and the first study to use breath analysis as a screening tool in adults with headaches. The actual incidence of occult CO intoxication in ED populations has varied from 2% to 23.6%. Some of this variance is certainly related to the fact that the very definition of an elevated CO level continues to be debated. In one study that only investigated venous COHB, a 7% incidence of unsuspected CO poisoning was found on all patients presenting to the ED with headaches, including those associated with fever and trauma [5] . A different group studied the incidence of CO poisoning in patients presenting with nonspecific flu-like symptoms and found a 23.6% incidence of venous COHb levels greater than 10%. That study also demonstrated elevated levels more frequently in patients using wood heat than in those using other sources of heat [6] . These studies indicate that CO poisonings, in its milder forms, may be difficult to identify from history and physical alone. Therefore, a high suspicion and ancillary testing are needed to make the diagnosis. Our results indicate that a positive value on breath analysis obtained from patients presenting with headaches, even as a secondary complaint, does in fact represent an elevated COHb level, as usually defined and confirmed by traditional testing. Other studies have been performed using CO breath analyzers but all have utilized different criteria for enrollment. In 1998, a CO breath analyzer was used as a screening tool in a convenience sample of all children, regardless of complaint, presenting to the ED. Two percent of that population had elevated COHb levels. In those with elevated breath levels, confirmatory cooximetric analysis of capillary blood was performed and found to correlate with COHb levels from the breath analyzer [7] . The analyzer has also been used by Turnbull to screen a convenience sample of all adults, regardless of complaint, presenting to an ED. He concluded that routine screening of ED patients for unsuspected CO exposure is not practical [8] . Recently, a study of 382 subjects who underwent breath analysis for CO and completed a questionnaire about possible sources of CO exposure showed breath analysis results correlated well with CO exposure. It did not specifically evaluate patients with symptoms of CO poisoning nor did it correlate their elevated levels with serum COHb levels [9] .
Our finding of a 7.1% incidence of elevated COHb levels in patients with headaches, patients not suspected of having CO poisoning, only reinforces the need for physicians to consider CO poisoning in the differential. Given the relatively low equipment costs (MicroCO Breath Analyzer $995, disposable cardboard breathing tube inserts $10/100 tubes) and ease of use, triage nurses could perform CO breath analysis on patients who present to the ED with the chief complaint of atraumatic, afebrile headaches. It should be noted that the main action taken in the treatment of our subjects was informing them of the need to have their home, work, and vehicle environments evaluated for sources of CO.
LIMITATIONS
Our study has limitations that should be noted. Most importantly we did not perform confirmatory venous COHb levels on those study subjects in whom CO breath analysis detected normal levels. Therefore, it is not possible to calculate the sensitivity or negative predictive value of the breath analyzer. However, the sensitivity of the device is reported by the manufacturer as 1 ppm or 0.0001% COHb [3] . Not all subjects had confirmatory venous testing. One subject refused to have their blood drawn, while the treating physician in two other cases failed to follow study protocol and obtain blood samples for analysis. Some gases (ethyl alcohol, hydrogen sulfide and sulfur dioxide) are noted to interfere with the breath analyzer; but in all cases, 100 ppm of the gas are required to produce a 1 ppm elevation on the MicroCO meter [3] . A history of alcohol intake was not obtained from our subjects or controls, but none of the subjects appeared clinically intoxicated. It is unlikely that small amounts of alcohol would have made a significant difference.
This study was not designed for follow up and the sources of CO exposure were not identified in the majority of subjects. However, the sources of exposure were known in two cases. One individual was found to have a faulty exhaust system in her new car and another individual's elevated level was caused by a poorly ventilated fireplace. We do not have knowledge of which individuals owned CO detectors, and we do not have knowledge of CO detector regulations in our area.
CONCLUSIONS
Noninvasive measurement of CO levels in ED patients with headaches is a rapid and specific method of screening for CO exposure. During the winter months, elevated CO levels are present in over 7% of ED patients presenting with headaches.
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